Nicotinamide Riboside (NR): What Human Clinical Data Really Shows

Nicotinamide Riboside (NR): What Human Clinical Data Actually Shows

Nicotinamide riboside (NR) is a vitamin B3–derived compound studied as a precursor to NAD⁺, a molecule essential for cellular energy production, mitochondrial function, immune regulation, and DNA repair.

In recent years, NR has been evaluated in multiple human studies. Below is a data-driven summary of what controlled clinical research shows — including exact numbers, timelines, and limitations.

Numbers First:

• NAD⁺ levels: ↑ ~2.6–3.1× within 5–10 weeks of NR intake.
• Dose studied: up to 2,000 mg/day in randomized trials.
• Clinical outcomes: no consistent statistically significant advantage vs placebo.
• Safety: generally well tolerated under clinical supervision.

Why NAD⁺ Is a Target in Human Research

NAD⁺ participates in hundreds of enzymatic reactions related to mitochondrial energy production, oxidative stress control, and cellular repair mechanisms.

Human observational and mechanistic studies show that NAD⁺ levels tend to decline with age and during chronic inflammatory or metabolic stress. This biological observation is what motivates research into NAD⁺ precursors such as NR.

Increasing NAD⁺ is a measurable biochemical effect. Whether that translates into meaningful clinical benefits depends on population, dose, and duration.

Key Human Trial: Randomized Controlled Data (2025)

One of the most detailed human studies to date was published in eClinicalMedicine (The Lancet Group, 2025).

• Design: double-blind, randomized, placebo-controlled
• Participants: 58 adults (long-COVID population)
• Duration: 24 weeks total
• NR dose: 2,000 mg/day

NAD⁺ Results

• NAD⁺ increased by ~3.1× after 5–10 weeks in the NR group (p < 0.001).
• Placebo phase showed no meaningful NAD⁺ increase.
• After crossover from placebo to NR, NAD⁺ rose to ~2.6×.

Clinical Outcomes

• No statistically significant differences between NR and placebo in primary cognitive tests.
• No significant between-group differences in fatigue, sleep quality, anxiety, or depression.
• Exploratory within-group analysis after ~10 weeks of NR showed:
  • ↓ fatigue scores (~3.8 points)
  • ↓ sleep disturbance scores (~0.7 points)
  • ↓ depression scores (~1.7 points)
  These findings were labeled hypothesis-generating.

Authors concluded that NR is effective at increasing NAD⁺ levels in humans, but that larger trials are required to confirm consistent clinical benefits.

View the full peer-reviewed study →

What the Evidence Supports — Clearly

Supported by data

• NR reliably increases circulating NAD⁺ levels in humans.
• NR has been tested at gram-level doses under clinical supervision.
• Biological effects on NAD⁺ occur within weeks, not months.

Not established

• That higher NAD⁺ automatically leads to symptom improvement.
• That NR works uniformly across all populations.
• That NR treats or prevents disease.

Sources

• Wu C-Y et al. Effects of nicotinamide riboside on NAD⁺ levels, cognition, and symptom recovery. eClinicalMedicine (2025). https://doi.org/10.1016/j.eclinm.2025.103633
• Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in humans. Nature Communications. https://www.nature.com/articles/ncomms12948
• Conze D et al. Safety assessment of nicotinamide riboside. Scientific Reports. https://www.nature.com/articles/s41598-019-46120-z